Silverarc Capital Management, LLC Krystal Biotech, Inc. Transaction History

Silverarc Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$108.01 - $179.35 $1.08 Million - $1.79 Million	10,000 New	10,000 $1.78 Million
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $5.14 Million - $6.17 Million	-47,410 Reduced 39.86%	71,531 $8.3 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $6.67 Million - $11.1 Million	84,927 Added 249.68%	118,941 $14 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $1.78 Million - $2.07 Million	-24,521 Reduced 41.89%	34,014 $2.72 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $119,334 - $151,011	1,890 Added 3.34%	58,535 $4.64 Million
Q3 2022 Oct 28, 2022	SELL	$64.85 - $82.4 $3.15 Million - $4.01 Million	-48,632 Reduced 46.19%	56,645 $3.95 Million
Q2 2022 Jul 25, 2022	BUY	$48.93 - $73.47 $2.88 Million - $4.32 Million	58,788 Added 126.46%	105,277 $6.91 Million
Q1 2022 May 13, 2022	SELL	$51.99 - $72.11 $9,410 - $13,051	-181 Reduced 0.39%	46,489 $3.09 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $1.86 Million - $4.12 Million	46,670 New	46,670 $3.27 Million

309

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.92B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.